Prof Benoit You speaks to ecancer about the ENDOLA trial that he presented at AACR 2022. This was a phase I/II trial which assessed the safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients.

The phase I trial was charged with determining the safety of the combination with Prof You reporting that it was well tolerated.

He also reports that the phase II trial efficacy data proved promising activity in this combination.